revenu beat trikafta launch continu
robust total revenu guidanc rais widen
pipelin look track despit slight impact covid-
rais pt
top-line bottom-lin beat revenu establish cf
product miss kalydeco orkambi symdeko due
convers patient trikafta trikafta beat lead
overal top-line beat vs con combin
moder spend vs con sg vs con result
ep beat vs con light trikafta robust uptak management
rais widen total revenu guidanc
keep guidanc element unchang non-gaap sg
non-gaap effect tax rate
takeaway call cf management mention two key factor
drive trikafta uptak includ persist complianc
patient high far due earli stage
launch management expect potenti variabl go forward
account updat guidanc revenu management clarifi
orkambi symkemvi sale grow ex-u driven recent
reimburs agreement cannib trikafta us management
state goal drug reach cf patient global
requir approv trikafta ex-u patient age year ii label
expans age year iii snda approv lower age us
aatd management announc program temporarili paus
due recent resum screen enrol management
provid greater detail time program process type diabet
management comment drug acquir semma differenti
competit therapi due fact includ fulli differenti islet
cell ii technolog islet cell along devic
circumv immunosuppres valid anim without exhibit
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
shortcom competitor therapi trikafta price management
agre approach follow recent icer report
addit management emphas reimburs trikafta us payer
patient speak benefit trikafta management plan
make chang trikafta price bd management highlight strong
balanc sheet allow addit deal strategi remain
trikafta launch remain robust pipelin progress despit slight
impact expect trikafta uptak acceler quarter
reflect guidanc investor may concern management
guidanc suggest potenti quarter believ rang
prudent given current uncertainti pipelin aatd remain key
catalyst look forward detail time believ good
news management start enrol patient continu view vertex
trikafta uptak life-cycl manag oper margin drive risk-reward
ow vertex see vertex
clear leader cf therapi believ
manag potenti deliv
ep overtim
efcaci data aatd mice model
suggest efcaci corrector
human therefor model includ
risk-adjust revenu corrector
believ potenti
competit cf believ vertex
signic advantag posit
on-market drug treat cf
popul model share
competitor long-term
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
trikafta penetr us
assum life-cycl extens extend
franchis also assum
penetr tripl therapi us
eu het/min
homozygot patient ww sale
cf aatd us eu
commerci success key
trikafta penetr us
assum mainten key cf franchis
life-cycl extens also assum
penetr tripl combin
homozygot heterozygot us
eu risk-adjust peak ww sale
cf aatd
view descript risk reward theme
trikafta penetr us
penetr us eu total
peak ww sale cf aatd
therapi peak
preclin compound advanc two new compound
trikafta cf ema approv eu
 aatd data updat phii studi patient
 fsg initi poc phii studi focal
trikafta cf approv australia switzerland
main driver vertex uptak
current therapi orkambi/kalydeco/trikafta
development/uptak corrector
china india
view explan region hierarchi
research highest favor quintil
competitor drug fail clinic fail achiev
trikafta penetr fall short expect
kalydeco sale fail meet expect
data clinic candid
data competit exce
clinic trial nda ling
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
